Ambitious Almirall Lays Out Ebglyss Launch Plans
The Spanish firm is all set to launch its atopic dermatitis drug in Germany later this month and is hopeful of a smooth reimbursement path across Europe.
You may also be interested in...
Dermatology-focused Almirall S.A. is partnering with Microsoft for generative artificial intelligence capabilities. It is the second generative AI-based collaboration announced by Almirall in several months.
Lilly Diabetes president Mike Mason is retiring, prompting a shifting of responsibilities among the executive team as the company gears up for key product approvals.
The Spanish group has revealed that eight out of ten atopic dermatitis patients treated with lebrikizumab maintained skin clearance after a year, which compares favorably with Sanofi and Regeneron's blockbuster Dupixent.